MedPath

Ionis Pharmaceuticals' ION582 Receives FDA Fast Track Designation for Angelman Syndrome Treatment

• ION582, developed by Ionis Pharmaceuticals, has been granted Fast Track designation by the FDA for treating Angelman syndrome. • This designation aims to expedite the development and review of ION582, addressing an unmet need for Angelman syndrome patients. • ION582 is designed to target and reduce the expression of the UBE3A-AS transcript in individuals with Angelman syndrome. • The FDA's decision underscores the potential of ION582 to significantly improve outcomes for those affected by this rare neurological disorder.

Ionis Pharmaceuticals announced that its investigational medicine, ION582, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of Angelman syndrome. This designation is intended to accelerate the development and review of new drugs and biologics that treat serious conditions and fill an unmet medical need.

Mechanism of Action

ION582 is an antisense oligonucleotide (ASO) designed to reduce the expression of the UBE3A-AS transcript in individuals with Angelman syndrome. Angelman syndrome is a rare neurogenetic disorder caused by loss-of-function of the maternally inherited UBE3A gene. Suppressing the UBE3A-AS transcript aims to unsilence the normally silenced paternal UBE3A allele, thus restoring UBE3A protein levels in the brain.

Clinical Significance

Angelman syndrome affects approximately 1 in 12,000 to 1 in 20,000 live births. Characteristics of Angelman syndrome include developmental delay, intellectual disability, severe speech impairment, movement disorders, and seizures. Currently, there are no approved therapies that address the underlying genetic cause of Angelman syndrome, highlighting the significant unmet medical need.
The Fast Track designation by the FDA is a crucial step in expediting the development of ION582, potentially bringing a much-needed therapy to patients and families affected by Angelman syndrome sooner. Ionis Pharmaceuticals is actively advancing the clinical development program for ION582, with ongoing trials assessing its safety and efficacy.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Spinogenix's SPG601 Shows Promise in Phase 2 Trial for Fragile X Syndrome

Spinogenix's SPG601 demonstrated a significant reduction in high-frequency gamma band activity, an EEG abnormality associated with Fragile X syndrome (FXS).
The Phase 2 trial met its primary endpoint, suggesting SPG601's potential to improve brain activity related to learning and memory in FXS patients.

Neurocrine Biosciences' Crinecerfont Receives FDA Approval for Congenital Adrenal Hyperplasia

The FDA has approved Crinecerfont, developed by Neurocrine Biosciences, as the first drug in decades for congenital adrenal hyperplasia (CAH).
Crinecerfont is designed to reduce elevated androgen levels in individuals with CAH, addressing a critical unmet need in current treatment.

Ionis Awaits FDA Decision on Olezarsen for Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals anticipates an FDA decision on olezarsen by December 19 for familial chylomicronemia syndrome (FCS).
Olezarsen aims to enhance the body's ability to break down fats, potentially treating a broader range of patients with high triglycerides.

FDA Gears Up for Year-End Decisions on Novel Therapies for Rare Diseases and Cancer

The FDA is set to decide on Ionis Pharmaceuticals' olezarsen for familial chylomicronemia syndrome (FCS), a rare genetic disease, by December 19, following positive Phase III results.
Lexicon Pharmaceuticals awaits the FDA's decision on sotagliflozin as an adjunct therapy for type 1 diabetes by December 20, despite concerns raised by an advisory committee.

FDA Grants Fast Track Designation to GNSC-001 Gene Therapy for Knee Osteoarthritis

The FDA has granted Fast Track designation to GNSC-001, a novel gene therapy for knee osteoarthritis, potentially expediting its development and review.
GNSC-001 is designed to deliver long-term inhibition of interleukin-1 (IL-1) by expressing an optimized form of IL-1 receptor antagonist (IL-1Ra) in the affected knee.

FDA Approves Abionic's CAPSULE PSP for Rapid Sepsis Detection

Abionic's CAPSULE PSP, a point-of-care diagnostic, has received FDA approval for early sepsis detection, enabling quicker clinical decision-making.
The device measures Pancreatic Stone Protein (PSP) levels, a biomarker that rises rapidly in response to bacterial infections leading to sepsis.

FDA Grants Fast Track Designation to Zilganersen for Alexander Disease

The FDA has granted Fast Track designation to zilganersen for treating Alexander disease (AxD), an ultra-rare neurological disorder.
Zilganersen, developed by Ionis Pharmaceuticals, is the first investigational medicine in clinical trials for AxD, addressing an unmet need.

Neuralink Receives FDA Breakthrough Device Designation for Vision Implant

Neuralink has been granted Breakthrough Device designation by the FDA for its innovative vision implant, aiming to restore sight to individuals with blindness.
The implant works by directly stimulating the brain, bypassing damaged eyes, and holds potential for treating various vision impairments.

NervGen Pharma Receives Fast Track Designation for NVG-291 in Spinal Cord Injury Treatment

NervGen Pharma Corp. has been granted Fast Track designation by the FDA for NVG-291, a novel treatment for spinal cord injury, aiming to expedite its development and review process. The Phase 1b/2a clinical trial is underway, with initial results anticipated by mid-2024.

Denali's Hunter Syndrome Candidate Receives FDA Orphan Drug and Rare Pediatric Disease Designations

Denali Therapeutics Inc. announced that its pipeline candidate, DNL310, has been granted orphan drug status and a rare pediatric disease designation by the FDA for the treatment of Hunter Syndrome, a rare lysosomal storage disease. The company plans to initiate a phase I/II study in 2020, following promising pre-clinical results.

Reference News

[1]
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag - Barchart.com
barchart.com · Oct 2, 2024

Switch Market flag for country-specific data. Right-click for chart options. Use arrows to navigate symbols.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy